ADDF Issues RFP for Projects to Accelerate Drug Discovery for Frontotemporal Degeneration

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

Grants of up to $150,000 will be awarded to support research investigating the pathologic mechanisms underlying FTD. Priority will be given to lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME, as well as the testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.

To be eligible, applicants must be an academic investigator seeking to create and support innovative translational programs in academic medical centers and universities or biotechnology companies with programs dedicated to neurodegenerative disease translational development. New biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding also are eligible to apply.

Letters of Intent must be received no later than July 13. Upon review, selected applicants will be invited to submit a full proposal by August 10, 2018.

See the ADDF website for complete program guidelines and application instructions.